Sedana Medical AB (DE:7D2A)
FRANKFURT:7D2A
Want to see DE:7D2A full AI Analyst Report?
7D2A Stock Chart & Stats
€0.90
-€0.09(-6.01%)
At close: 4:00 PM EST
€0.90
-€0.09(-6.01%)
Day’s Range― - ―
52-Week Range€0.72 - €1.52
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€93.41M
Enterprise Value€942.11M
Total Cash (Recent Filing)€80.68M
Total Debt (Recent Filing)€7.56M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Jul 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding99,336,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€19.70M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageAn extremely low debt load gives Sedana durable financial flexibility while it scales commercial and regulatory activities. With limited interest burden, management can fund R&D and market rollout from equity/liquidity, reducing near-term default risk during cash burn.
High Gross MarginsSustained ~71% gross margins indicate strong unit economics from devices and drug sales. If top-line growth resumes, high gross margins provide room to absorb SG&A and scale to profitability, making margin sustainability a structural advantage for long-term operating leverage.
Consumable + Drug Revenue ModelA consumable-heavy model tied to each ventilated patient creates recurring, per-patient revenue and predictable repurchase cycles. Coupled with proprietary drug commercialization, this supports durable revenue per customer and scale benefits as hospital adoption deepens over time.
Bears Say
Structural Operating LossesPersistent negative EBIT and large net losses erode shareholder value and signal that current revenue and cost structure do not yet generate operating profit. Without sustained margin improvement or revenue expansion, losses will continue to pressure equity and strategic options.
Negative Cash GenerationSubstantial negative operating and free cash flow increases reliance on existing liquidity or external financing to fund commercialization and regulatory work. Over the medium term this constrains investment flexibility and may force dilution or cutbacks if cash burn persists.
Weak Revenue MomentumFlat-to-declining trailing revenues limit the company's ability to convert high gross margins into operating profits. Slow adoption of inhaled ICU sedation or limited geographic rollout undermines scale economics and delays the path to sustainable profitability.
Sedana Medical AB News
7D2A FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was €0.72 and its highest was €1.52 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is €93.41M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Jul 17, 2026 which is in 77 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Apr 23, 2026. The company reported -€0.004 earnings per share for the quarter, beating the consensus estimate of -€0.004 by <€0.001.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is >-0.01.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -€0.004 in its last earnings report, beating expectations of -€0.004. Following the earnings report the stock price went down -5.234%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in DE:7D2A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---